ISPECIMEN INC (ISPC)
US45032V1089 - Common Stock
Overall ISPC gets a fundamental rating of 3 out of 10. We evaluated ISPC against 37 industry peers in the Health Care Technology industry. While ISPC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ISPC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ISPC had negative earnings in the past year.
In the past year ISPC has reported a negative cash flow from operations.
ISPC had negative earnings in each of the past 5 years.
In the past 5 years ISPC always reported negative operating cash flow.
1.2 Ratios
ISPC has a worse Return On Assets (-84.55%) than 86.11% of its industry peers.
ISPC has a Return On Equity of -202.01%. This is amonst the worse of the industry: ISPC underperforms 80.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.55% | ||
| ROE | -202.01% | ||
| ROIC | N/A |
ROA(3y)-45.63%
ROA(5y)-64.82%
ROE(3y)-64.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ISPC's Gross Margin of 47.97% is on the low side compared to the rest of the industry. ISPC is outperformed by 61.11% of its industry peers.
ISPC's Gross Margin has improved in the last couple of years.
ISPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.92%
GM growth 5Y2.16%
2. Health
2.1 Basic Checks
ISPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ISPC has been reduced compared to 1 year ago.
The number of shares outstanding for ISPC has been reduced compared to 5 years ago.
There is no outstanding debt for ISPC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ISPC has an Altman-Z score of -10.00. This is a bad value and indicates that ISPC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.00, ISPC is doing worse than 86.11% of the companies in the same industry.
ISPC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
A Current Ratio of 0.74 indicates that ISPC may have some problems paying its short term obligations.
ISPC has a Current ratio of 0.74. This is amonst the worse of the industry: ISPC underperforms 80.56% of its industry peers.
ISPC has a Quick Ratio of 0.74. This is a bad value and indicates that ISPC is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ISPC (0.74) is worse than 80.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
ISPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.26%, which is quite good.
The Revenue has been growing slightly by 0.69% in the past year.
ISPC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.73% yearly.
EPS 1Y (TTM)17.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.35%
Revenue 1Y (TTM)0.69%
Revenue growth 3Y6.67%
Revenue growth 5Y17.73%
Sales Q2Q%-4.24%
3.2 Future
ISPC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.24% yearly.
ISPC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.14% yearly.
EPS Next Y96.29%
EPS Next 2Y40.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.58%
Revenue Next 2Y9.14%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ISPC. In the last year negative earnings were reported.
Also next year ISPC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ISPC's earnings are expected to grow with 40.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.24%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ISPC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ISPECIMEN INC
NASDAQ:ISPC (12/18/2024, 3:48:07 PM)
4.2202
+0.9 (+27.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.05M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.55% | ||
| ROE | -202.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.97% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)17.26%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y96.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)0.69%
Revenue growth 3Y6.67%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y